GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viracta Therapeutics Inc (FRA:RYI) » Definitions » Accumulated other comprehensive income (loss)

Viracta Therapeutics (FRA:RYI) Accumulated other comprehensive income (loss) : €-0.01 Mil (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Viracta Therapeutics Accumulated other comprehensive income (loss)?

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings. Viracta Therapeutics's Accumulated other comprehensive income (loss) for the quarter that ended in Mar. 2024 was €-0.01 Mil.

Viracta Therapeutics's quarterly Accumulated other comprehensive income (loss) increased from Sep. 2023 (€-0.06 Mil) to Dec. 2023 (€0.01 Mil) but then declined from Dec. 2023 (€0.01 Mil) to Mar. 2024 (€-0.01 Mil).

Viracta Therapeutics's annual Accumulated other comprehensive income (loss) declined from Dec. 2021 (€0.00 Mil) to Dec. 2022 (€-0.17 Mil) but then increased from Dec. 2022 (€-0.17 Mil) to Dec. 2023 (€0.01 Mil).

Viracta Therapeutics Accumulated other comprehensive income (loss) Historical Data

The historical data trend for Viracta Therapeutics's Accumulated other comprehensive income (loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viracta Therapeutics Accumulated other comprehensive income (loss) Chart

Viracta Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Accumulated other comprehensive income (loss)
- - -0.17 0.01

Viracta Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Accumulated other comprehensive income (loss) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.08 -0.11 -0.06 0.01 -0.01

Viracta Therapeutics Accumulated other comprehensive income (loss) Calculation

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings.

Viracta Therapeutics Accumulated other comprehensive income (loss) Related Terms

Thank you for viewing the detailed overview of Viracta Therapeutics's Accumulated other comprehensive income (loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Viracta Therapeutics (FRA:RYI) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viracta Therapeutics Inc (FRA:RYI) » Definitions » Accumulated other comprehensive income (loss)
Comparable Companies
PIRS NRXP MRKR ENLV NCNA ORGS SRNEQ ABIO CADL RGLS OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
VIRX:USA RYIS:Germany
Address
2533 South Coast Highway 101, Suite 210, Cardiff, CA, USA, 92007
Website
https://www.viracta.com
Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. Its lead product candidate is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people who have received organ transplants.